Proactive Investors - Run By Investors For Investors

Summit Therapeutics sees a bright future for its antibiotics programmes

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM), spoke to Proactive's Andrew Scott following the disappointing results from the mid-stage study of their Duchenne muscular dystrophy drug.

Edwards says one of the key focuses going forward is Ridinilazole, Summit’s lead candidate, which is due to enter phase III trials in the first quarter of 2019.

Using their Discuva drug discovery platform, the company's also identified two possible compounds for gonorrhoea – a sexually transmitted infection which affects an estimated 78mln people every year.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use